PAMS
CORT icon

Pictet Asset Management (Switzerland)’s Corcept Therapeutics CORT Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$232K Sell
10,437
-2,248
-18% -$51.7K ﹤0.01% 1645
2023
Q1 		$275K Buy
12,685
+2,388
+23% +$52.4K ﹤0.01% 1549
2022
Q4 		$209K Buy
+10,297
New +$258K ﹤0.01% 1713

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s CORT Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) reduced its Corcept Therapeutics (CORT) stake by 18% in Q2 2023, selling an estimated $51.7K and leaving 10,437 shares worth $232K. The position accounts for ﹤0.01% of the portfolio, ranked #1645.

Pictet Asset Management (Switzerland) first reported a position in CORT in Q4 2022 and has held it in 3 quarters since. The position peaked at $275K in Q1 2023. 225 funds tracked by Wall St. Rank hold CORT as of Q2 2023.

  • Pictet Asset Management (Switzerland) held 10,437 shares of Corcept Therapeutics worth $232K as of Q2 2023.
  • Pictet Asset Management (Switzerland) sold 2,248 Corcept Therapeutics shares in Q2 2023, an estimated $51.7K.
  • Corcept Therapeutics made up ﹤0.01% of Pictet Asset Management (Switzerland)'s portfolio in Q2 2023, its #1645 holding.
  • Pictet Asset Management (Switzerland) first reported a position in Corcept Therapeutics in Q4 2022 and has held it in 3 quarters since.
  • Pictet Asset Management (Switzerland)'s Corcept Therapeutics position peaked at $275K in Q1 2023.
  • 225 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.